
|Articles|April 15, 2006
More study needed before combination therapies for AMD accepted
Baltimore?Photodynamic therapy (PDT) has been the mainstay of treatment for choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD) until recently when combination therapies (PDT and anti-vascular endothelial growth factor [VEGF]) agents started to be explored.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement




























